Zydus Lifesciences Ltd has achieved a significant regulatory milestone by securing its first drug approval in China, with the National Medical Products Administration (NMPA) clearing Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths for treating multiple psychiatric conditions.
Therapeutic Applications and Mechanism
The approved Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The medication works by helping restore the balance of serotonin and norepinephrine in the brain to improve mood and reduce anxiety.
Manufacturing and Production
Venlafaxine ER Capsules will be manufactured at Zydus' existing facility in Moraiya, Ahmedabad. This production arrangement allows the company to leverage its established manufacturing infrastructure to serve the Chinese market.
Strategic Significance for Zydus
This approval represents Zydus Lifesciences' inaugural regulatory success with the NMPA, establishing the company's presence in China's pharmaceutical market. The achievement comes as part of Zydus' broader expansion strategy in international markets.
Pipeline Development in China
Beyond this approval, Zydus has been advancing other therapeutic programs in China. In August, the company announced completion of clinical trials for Desidustat, a novel oral drug for treating anaemia in patients with Chronic Kidney Disease (CKD), and is preparing for commercial launch with its Chinese partner.
Company Profile
Zydus Lifesciences operates as a global lifesciences company that discovers, develops, manufactures, and markets healthcare therapies across multiple therapeutic areas. Over the past decade, the company has introduced several products addressing unmet healthcare needs, including vaccines, therapeutics, biologicals, and New Chemical Entities.
